Kymera Therapeutics (KYMR) Non-Current Deffered Revenue (2019 - 2025)
Historic Non-Current Deffered Revenue for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $14.0 million.
- Kymera Therapeutics' Non-Current Deffered Revenue changed N/A to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year change of. This contributed to the annual value of $16.8 million for FY2023, which is 4011.43% down from last year.
- As of Q3 2025, Kymera Therapeutics' Non-Current Deffered Revenue stood at $14.0 million.
- In the past 5 years, Kymera Therapeutics' Non-Current Deffered Revenue registered a high of $64.7 million during Q1 2021, and its lowest value of $3.2 million during Q2 2024.
- Over the past 5 years, Kymera Therapeutics' median Non-Current Deffered Revenue value was $24.1 million (recorded in 2022), while the average stood at $28.7 million.
- Examining YoY changes over the last 5 years, Kymera Therapeutics' Non-Current Deffered Revenue showed a top increase of 436.34% in 2024 and a maximum decrease of 8438.37% in 2024.
- Quarter analysis of 5 years shows Kymera Therapeutics' Non-Current Deffered Revenue stood at $39.3 million in 2021, then decreased by 28.74% to $28.0 million in 2022, then tumbled by 40.11% to $16.8 million in 2023, then crashed by 80.98% to $3.2 million in 2024, then skyrocketed by 337.66% to $14.0 million in 2025.
- Its Non-Current Deffered Revenue stands at $14.0 million for Q3 2025, versus $3.2 million for Q2 2024 and $23.8 million for Q1 2024.